Physicians Research Group II LLC

1. Taro Pharmaceuticals USA, Inc. $345,207 104 payments
2. Sanofi US Services Inc. $260,686 48 payments
3. Mitsubishi Tanabe Pharma America, Inc. $246,247 126 payments
4. Janssen Research & Development, LLC $172,979 41 payments
5. Biohaven Pharmaceutical Holding Company Ltd. $165,135 28 payments
6. Sun Pharmaceutical Industries Inc. $136,142 46 payments
7. Journey Medical Corporation $133,200 9 payments
8. Eli Lilly and Company $133,152 22 payments
9. Pfizer Inc. $111,918 33 payments
10. Amgen Inc. $87,585 4 payments

1. A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo $181,833 35 payments
2. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $151,655 34 payments
3. Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata $136,142 46 payments
4. Phase 3 Multicenter Openlabel Study to Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $119,746 30 payments
5. A Phase 3, Multicenter, Open-Label, Long-Term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (Mt-7117) in Subjects With Erythropoietic Protoporphyria (Epp) Or X-Linked Protoporphyria (XLP) $105,070 70 payments
6. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis $101,138 37 payments
7. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability Ofmt-7117In Adults and Adolescents With Erythropoietic Protoporphyria Or X-Linked Protoporphyria $100,857 31 payments
8. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $92,599 10 payments
9. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $90,380 16 payments
10. Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD $89,884 17 payments

1. Professional salary support $10,306 7 payments
2. Patient care $9,723 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.